Tissue engineering: the end of the beginning.

This study was undertaken to assess the impact of current economic conditions and recent disappointing product launches on the field of tissue engineering. Data were collected on all firms known to be active in the field, analyzed, and compared with analogous data collected in 1995, 1998, and 2000. As of December 31, 2002, more than 2600 full-time equivalents (FTEs) in 15 countries and 89 firms were engaged in tissue-engineering research and development. Annual spending was US dollars 487 million, down about 20% since 2000-a reasonable performance in the face of a stagnant economy and difficult capital markets. Individual sectors proved far more volatile. Activity in skin, cartilage, and other structural applications declined by more than 50% with a loss of 800 FTEs. This downsizing was somewhat counterbalanced by a 42% increase in stem cell firms, which added more than 300 employees. Consistent with general disenchantment with technology sector equities, capital value of publicly traded tissue-engineering corporations has decreased by almost 90% from US dollars 2.5 billion at the end of 2000 to US dollars 300 million at the end of 2002. The United States' fraction of the total workforce declined from 80% in 2000 to 54% in 2002. By the close of 2002, twenty tissue-engineered products had entered Food and Drug Administration clinical trials. Four were approved but none of these are yet commercially successful. Six other applications were either abandoned or failed to achieve product approval. Ten products were still in clinical trials, some of which were investigator sponsored, and most of which were at the phase I/phase II stage. The field has yet to produce a profitable product despite an aggregate research and development investment exceeding US dollars 4.5 billion. Tissue engineering is clearly having difficulty transitioning from a development stage industry to one with a successful product portfolio. This is often the case for breakthrough medical technologies.

[1]  M J Lysaght.  Product development in tissue engineering. , 1995, Tissue engineering.

[2]  Larry V McIntire.  WTEC panel report on tissue engineering. , 2003, Tissue engineering.

[3]  B. Bay,et al.  Evaluation of cell culture on the polyurethane-based membrane (TegadermTM): implication for tissue engineering of skin , 2004, Cell and Tissue Banking.

[4]  Katrina Nordström,et al.  Current issues in the regulation of human tissue-engineering products in the European Union. , 2005, Tissue engineering.

[5]  William Bonfield,et al.  Designing porous scaffolds for tissue engineering , 2006, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[6]  Kevin M. Shakesheff,et al.  Altered cellular response to adsorbed matrix protein by chemoselective ligation of small molecules , 2005 .

[7]  D J Williams,et al.  Tissue engineering and regenerative medicine: manufacturing challenges. , 2005, IEE proceedings. Nanobiotechnology.

[8]  M J Lysaght,et al.  The growth of tissue engineering. , 2001, Tissue engineering.

[9]  M Helen Grant,et al.  Metabolic studies of hepatocytes cultured on collagen substrata modified to contain glycosaminoglycans. , 2005, Tissue engineering.

[10]  J. Elisseeff,et al.  Injectable cartilage tissue engineering , 2004, Expert opinion on biological therapy.

[11]  David Williams,et al.  25 Tissue engineering: the multidisciplinary epitome of hope and despair , 2005 .

[12]  Carl Sandburg.  Good Morning, America , 1928 .

[13]  Gerd Geerling,et al.  Adnexal Surgery for Severe Ocular Surface Disease , 2005, Seminars in ophthalmology.

[14]  Richard Archer,et al.  Why tissue engineering needs process engineering , 2005, Nature Biotechnology.

[15]  M J Lysaght,et al.  An economic survey of the emerging tissue engineering industry. , 1998, Tissue engineering.

[16]  C. W. G. Ansell,et al.  Tissue engineering: the challenges ahead , 2005 .

[17]  B. Zauscher,et al.  Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. , 2005, Transplantation.

[18]  L. Griffith,et al.  Tissue Engineering--Current Challenges and Expanding Opportunities , 2002, Science.

[19]  Jae-Hyung Jang,et al.  Gene delivery from polymer scaffolds for tissue engineering , 2004, Expert review of medical devices.

[20]  R. Munzner,et al.  Regulatory issues , 2005, Alzheimer's & Dementia.

[21]  T. Hunziker,et al.  Autologer kultivierter Hautersatz , 2004, Der Hautarzt.

[22]  M. Papadaki.  Cellular/tissue engineering , 2004, IEEE Engineering in Medicine and Biology Magazine.

[23]  Michael J. Lysaght.  Editorial: California's Proposition 71 , 2005 .

[24]  Masahiro Kino-Oka,et al.  A kinetic modeling of chondrocyte culture for manufacture of tissue-engineered cartilage. , 2005, Journal of bioscience and bioengineering.

[25]  Masahiro Kino-Oka,et al.  Bioreactor design for successive culture of anchorage-dependent cells operated in an automated manner. , 2005, Tissue engineering.